



CLAIMS

1. Use of a compound of formula (I) or a 3-enol C₁ to 4 alkanoate ester thereof in
the manufacture of a medicament for the treatment of an angiotensin II related
5 disease in humans and animals




10

wherein R₁, R₂, R₅, R₆ are the same or different and each is hydrogen or C₁ to 4 alkyl;
R₃ is hydrogen, C₁ to 4 alkyl, C₂ to 4 alkenyl or C₂ to 4 alkynyl;
R₄ is hydroxyl, C₁ to 4 alkanoyloxy, a group of formula (II) or (III)



15

(II)



(III)

20

wherein R₇ is (CH₂)_n, where n is an integer of from 0 to 4, R₈ is hydrogen, C₁ to 4 alkyl, hydroxy or NH₂ and R₉ and R₁₀ are the same or different and each is hydrogen or C₁ to 4 alkyl;
or R₃ and R₄ together are oxo, ethylenedioxy or propylenedioxy.

2. Use according to claims 1, wherein in formula (I) R₁ is hydrogen or methyl and/or R₂ is hydrogen or methyl and/or R₄ is hydroxy or R₃ and R₄ together are oxo and/or R₅ and R₆ are methyl.

5 3. Use according to claim 1, wherein the compound of formula (I) is trilostane, ketotrilostane or epostane.

4. Use according to any one of claims 1 to 3, wherein the angiotensin II related disease is a cardiovascular disease.

10

5. Use according to claim 4, wherein the cardiovascular disease is congestive heart failure, post myocardial infarction, cardiomyopathy, diabetes, renal failure, metabolic syndrome (Syndrome X) or arrhythmia.

15

6. Use according to claim 4, wherein the cardiovascular disease is post myocardial infarction.

7. Use according to any one of the preceding claims, wherein the medicament is administered in an amount of from 0.5 to 4 mg/kg/day.

20

8. Use according to any one of claims 1 to 3, wherein the angiotensin II related disease is a proliferative disease.

25

9. Use according to claim 8, wherein the proliferative disease is peripheral arterial disease, cerebro vascular disease, atheroma, cardiofibrosis, cardiac myopathy, diabetic retinopathy, diabetic gangrene, diabetic nephropathy, scleroderma, aneurism, asthma or atheroma.

30

10. Use according to claim 8 or claim 9, wherein the proliferative disease is cardiofibrosis.

11. Use according to any one of claims 8 to 10, wherein the proliferative disease is cardiofibrosis following infarction.

12. Use according to any one of the preceding claims, wherein the medicament is
5 administered in an amount of from 0.5 to 4 mg/kg/day.

13. Use according to any of the preceding claims wherein the medicament comprises the compound of formula (I) or a 3-enol C₁ to 4 alkanoate ester thereof as defined in claims 1 to 3, in particulate form.

10

14. Use according to claim 13 wherein the particles of the particulate form compound have a mean equivalent sphere volume diameter of up to 12 µm and 95% or more of the particles have a particle size of up to 50 µm.

15

15. Use according to claim 13 or claim 14 wherein the particles have a mean equivalent sphere volume diameter of from 5 to 12 µm.

16. Use according to any one of claims 13 to 15 wherein the particles have a mean equivalent sphere volume diameter of up to 5 µm.

20

17. Use according to any one of claims 13 to 16 wherein the specific surface area of the particulate compound is 2 m²g⁻¹ or higher or 5 m²g⁻¹ or higher.

25

18. Use according to any one of the preceding claims wherein the medicament is administered orally either as a tablet, a capsule or a liquid dispersion.

19. Use according to any one of the preceding claims wherein the medicament comprises a unit dosage of from 0.25 mg to 1000 mg of a compound of formula (I) or a 3-enol C₁ to 4 alkanoate ester thereof as defined in claims 1 to 3.

30

20. Use according to claim 19 wherein the unit dosage is from 0.5 mg to 25 mg.

21. Use according to claim 19, wherein the unit dosage is from 25 to 1000 mg.

22. Use according to any one of the preceding claims wherein the treatment of an angiotensin II related cardiovascular disease with a compound of formula (I) or a 3-

5 enol C₁ to 4 alkanoate ester thereof is carried out in combination with a further treatment of one or more of:

- an Angiotensin Converting Enzyme (ACE) inhibitor;
- an angiotensin II receptor blocker;
- an aldosterone inhibitor or agent used for lowering aldosterone levels or
10 blocking the effects of aldosterone in the body; or
- a steroidogenesis inhibitor.

23. Use according to claim 22 wherein the inhibitor or agent used for lowering aldosterone levels is an ACE inhibitor.

15

24. Use according to claim 22 or 23 wherein the ACE inhibitor is Captopril, Enalopril or Lisinopril.

25. Use according to claim 22 wherein the aldosterone inhibitor or agent for
20 blocking the effects of aldosterone is Spironolactone or Eplerenone.

26. Use according to claim 22 wherein the angiotensin II receptor blocker is Losartan or Candasartan.

25 27. Use according to claim 22 wherein the steroidogenesis inhibitor is aminoglutethimide or metyrapone.

28. A medicament comprising:

- (a) a compound of formula (I) or a 3-enol C₁ to 4 alkanoate ester thereof as
30 defined in claims 1 to 3 and 13 to 17; and
- (b) one or more of:
 - an ACE inhibitor;

- an angiotensin II receptor blocker;
- an inhibitor or agent used for lowering aldosterone levels or blocking the effects of aldosterone; or
- a steroidogenesis inhibitor

5 as defined in any one of claims 22 to 27, for simultaneous, separate or sequential use in the treatment of an angiotensin II related disease as defined in any one of claims claim 4 to 6 or 8 to 11.

29. A method of treating an angiotensin II related disease by administering to a 10 patient having said disease a compound of formula (I) or a 3-enol C_{1to4} alkanoate ester thereof as defined in any one of claims 1 to 3 or 13 to 17 in an amount effective to treat said disease.

30. A method of treating an angiotensin II related disease by administering to a 15 patient having said disease an amount of a compound of formula (I) or a 3-enol C_{1to4} alkanoate ester thereof as defined in any of claims 1 to 3 or 13 to 17 and an amount of one or more of:

- an ACE inhibitor;
- an angiotensin II receptor blocker;
- an aldosterone inhibitor or agent for lowering aldosterone levels or blocking the effects of aldosterone; or
- a steroidogenesis inhibitor

effective to treat said disease.

25 31. A method according to claim 29 or 30 wherein the angiotensin II related is a disease as defined according to claim 4 to 6 or 8 to 11.